The Latest Cardiac and Vascular News
TACOMA, Wash., July 31, 2025 /PRNewswire/ — Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to RNS60, its lead…
Trial met primary endpoints of similar rates of serious adverse events (SAEs) and fewer deaths observed with RNS60 versus placebo Statistically significant reduction in infarct growth (brain tissue loss) – a secondary endpoint – in patients treated with RNS60 adjunct to endovascular…
TACOMA, Wash., May 21, 2025 /PRNewswire/ — Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced data from a post hoc analysis of its completed Phase 2 RESCUE clinical trial, showing that ischemic stroke…
Reduced hospital stays with more patients discharged to home when treated with RNS60 Results presented during oral presentation at the American Academy of Neurology 2025 Annual Meeting TACOMA, Wash., April 9, 2025 /PRNewswire/ — Revalesio, a clinical-stage pharmaceutical company…
Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient’s recovery TACOMA, Wash.,…
TACOMA, Wash.–(BUSINESS WIRE)–Revalesio, a clinical-stage pharmaceutical company developing treatments for neurological diseases, presented the design of its recently launched RESCUE Phase 2 clinical trial evaluating RNS60 as a treatment for large vessel occlusion acute ischemic stroke (AIS), as well as new preclinical data supporting the advancement of RNS60 for AIS. […]
